Comparison of Changes in Blood Pressure Measurements and Antihypertensive Therapy in Older, Hypertensive, Ambulatory Care Patients Prescribed Celecoxib or Rofecoxib

Pharmacotherapy

Volumn 23, Issue 11, 2003, Pages 1416-1423

  Nietert, Paul J ^a   Ornstein, Steven M ^a   Dickerson, Lori M ^a   Rothenberg, Ralph J ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LACTONE; LOOP DIURETIC AGENT; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; SULFONAMIDE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; AMBULATORY CARE; ANTIHYPERTENSIVE THERAPY; ARTHRITIS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHI SQUARE DISTRIBUTION; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; LACTONES; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; RETROSPECTIVE STUDIES; SULFONAMIDES; SULFONES;

EID: 0142151535     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.14.1416.31935     Document Type: Article

References (35)

1. American Geriatric Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50:5205-24.
2. American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, IL: American Pain Society, 2002.
3. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
4. Pharmacia Co. and Pfizer, Inc. Celebrex (celecoxib) package insert. New York, NY; 2002.
5. Merck & Co., Inc. Vioxx (rofecoxib) package insert. Whitehouse Station, NJ; 2002.
6. Williams GW, Ettlinger RE, Ruderman EM, et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib. J Clin Rheumatol 2000;6:65-74.
7. Day R, Morrison B, Luza A et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/ibuprofen comparator study group. Arch Intern Med 2000;160:1781-7.
8. McKenna F, Weaver A, Fiechtner JJ, et al. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J Clin Rheumatol 2001;7:151-9.
9. Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
10. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
11. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000;284:1247-55.
12. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
13. Desai MM, Zhang P, Hennessy CH. Surveillance for morbidity and mortality among older adults - United States, 1995-1996. CDC surveillance summary. MMWR Morb Mortal Wkly Rep 1999;48:7-25.
14. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991;90:42S-7.
15. Singh G, Miller JD, Lee FH, Pettit D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the third national health and nutrition examination survey. Am J Manag Care 2002;8:S383-91.
16. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70.
17. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133:1-9.
18. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107:65S-70.
19. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24.
20. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84.
21. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
22. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777-84.
23. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-12.
24. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997;17:277-89.
25. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-3.
26. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30.
27. Whelton A, Singh G, White W, et al. Celecoxib does not increase the risk of cardiac failure, edema, or hypertension compared to NSAIDs: results from SUCCESS 1, a double blind, randomized trial in 13.274 OA patients. Presented at the 2001 annual congress of the European League Against Rheumatism. Available from www.eular.org. Accessed September 1, 2003.
28. Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. Arthritis Rheum 2002;47:349-55.
29. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > 65 years of age with systemic hypertension and osteoarthritits. Am J Cardiol 2002;90:959-63.
30. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
31. Garnett WR. Clinical implications of drug interactions with coxibs. Pharmacotherapy 2001;21:1223-32.
32. Armstrong EP, Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003;25:1-18.
33. Osterhaus JT, Burke TA, May C, Wentworth C, Whelton A, Bristol S. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. Clin Ther 2002;24:969-89.
34. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Am J Manag Care 2002;8:S401-13.
35. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.